17ß-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period

Grzegorz Stachowiak; Tomasz Pertyński

Abstract

1/2010 vol. 9

Review paper

17ß-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period

Grzegorz Stachowiak

,

Tomasz Pertyński

Przegląd Menopauzalny 2010; 1: 1–4

Online publish date: 2010/02/25

View full text

AMA

Stachowiak G, Pertyński T. 17ß-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period. Menopause Review/Przegląd Menopauzalny. 2010;9(1):1-4.

APA

Stachowiak, G., & Pertyński, T. (2010). 17ß-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period. Menopause Review/Przegląd Menopauzalny, 9(1), 1-4.

Chicago

Stachowiak, Grzegorz, and Tomasz Pertyński. 2010. "17ß-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period". Menopause Review/Przegląd Menopauzalny 9 (1): 1-4.

Harvard

Stachowiak, G., and Pertyński, T. (2010). 17ß-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period. Menopause Review/Przegląd Menopauzalny, 9(1), pp.1-4.

MLA

Stachowiak, Grzegorz et al. "17ß-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period." Menopause Review/Przegląd Menopauzalny, vol. 9, no. 1, 2010, pp. 1-4.

Vancouver

Stachowiak G, Pertyński T. 17ß-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period. Menopause Review/Przegląd Menopauzalny. 2010;9(1):1-4.

Low-dose oral MHT combining 1 mg oestradiol (E2) and 2 mg drospirenone (DRSP) is effective in alleviating climacteric and urogenital symptoms, prevents endometrial hyperplasia, reduces the risk of osteoporosis, and has a positive influence on lipid profile, carbohydrate metabolism, arterial pressure and female quality of life. This safe type of MHT can be a drug of first choice for the big group of women after menopause.